GliomaGlioblas peptide vaccine - immatics/BioNTech

Drug Profile

GliomaGlioblas peptide vaccine - immatics/BioNTech

Alternative Names: Actively personalized vaccines (APVACs); APVAC1; APVAC2

Latest Information Update: 08 Jul 2016

Price : $50

At a glance

  • Originator Glioma Actively Personalized Vaccine Consortium
  • Developer BioNTech; immatics biotechnologies GmbH
  • Class Cancer vaccines; Peptide vaccines; Peptides
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Glioblastoma

Most Recent Events

  • 16 Apr 2016 Interim adverse events data from a phase I trial in Glioblastoma presented at the 107th Annual Meeting of the American Association for Cancer Research (AACR 2016)
  • 14 Oct 2014 Phase-I/II clinical trials in Glioblastoma (Adjunctive treatment, Combination therapy, Early-stage disease) in Germany (Parenteral)
  • 17 Jul 2014 Immatics plans a phase I trial for Glioblastoma (Adjunctive treatment, Combination therapy, Early-stage disease) in Germany, Switzerland, United Kingdom, Spain, Netherlands, Denmark and USA (NCT02149225)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top